LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2018. For the second quarter of 2018, worldwide sales from continuing operations were $287.5 million, an increase of 12.4 percent on a reported basis and an increase of 10.2 percent on […]
Author: Ken Dropiewski
Infraredx Announces Launch of Makoto™ Intravascular Imaging System and Dualpro™ IVUS+NIRS Catheter in Japan
BURLINGTON, Mass.–(BUSINESS WIRE)–Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, today announced the Makoto™ Intravascular Imaging System, and accompanying Dualpro™ intravascular ultrasound and near-infrared spectroscopy (IVUS+NIRS) catheter, is now available in Japan. The launch follows a successful Spring 2018 limited market release, which included more than […]
Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director
TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory News: Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the oncology field announces today the […]
GE Healthcare and Lantheus Announce Start of a Phase 3 Clinical Trial of Flurpiridaz, an Investigational Agent Being Evaluated for the Detection of Coronary Artery Disease
BOSTON & NORTH BILLERICA, Mass.–(BUSINESS WIRE)–GE Healthcare and Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (collectively “Lantheus”), have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the […]
Thermedical Announces FDA Investigational Device Exemption Approval to Begin US Clinical Study of Durablate Catheter for Treatment of Ventricular Tachycardia
WALTHAM, Mass.–(BUSINESS WIRE)–Thermedical® announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for the Early Feasibility Study (EFS) of the groundbreaking Durablate™ ablation catheter. The single-arm, observational study is designed to evaluate the safety and effectiveness of the Durablate catheter to […]
Cardiovascular Systems, Inc. Reports Fiscal 2018 Fourth-Quarter Financial Results
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal fourth quarter, ended June 30, 2018. CSI’s fourth-quarter revenues were $59.2 million, an increase of $6.2 million […]
Merit Medical to Present at Two Conferences in August
SOUTH JORDAN, Utah, July 31, 2018 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will participate at two conferences in August. […]
Merit Medical Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option
SOUTH JORDAN, Utah, July 30, 2018 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ:MMSI) (“Merit”), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it closed its previously announced underwritten public […]
Stereotaxis to Report Second Quarter 2018 Financial Results on August 7, 2018
ST. LOUIS, July 31, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 second quarter ended June 30, 2018 on Tuesday, August 7, 2018 before the open of […]
Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage
Tokyo, Japan and Toronto, Ontario, July 31, 2018 (GLOBE NEWSWIRE) — Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc. (Tokyo, TYO:4563), a Japan-based biotechnology company focused on developing biotherapeutics, announce the signing of an innovative global Co-Development Agreement for the development and commercialization of […]



